Nektar Therapeutics
NKTR
246 hedge funds and large institutions have $2.93B invested in Nektar Therapeutics in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 80 increasing their positions, 87 reducing their positions, and 38 closing their positions.
96% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $10.6M
2% more capital invested
Capital invested by funds: $2.88B → $2.93B (+$52.2M)
0.06% less ownership
Funds ownership: 6.46% → 6.41% (-0.06%)
3% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 38
8% less repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 87
1% less funds holding
Funds holding: 249 → 246 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$16.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$13.6M |
| 3 |
Millennium Management
New York
|
+$8.77M |
| 4 |
D.E. Shaw & Co
New York
|
+$7.69M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.3M |
| 2 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$12.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.5M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$9.96M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$9.81M |
NKTR Hedge Fund Activity: Q4 2020 in Review
246 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2020, worth a combined $2.93B — up 1.8% from $2.88B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of NKTR and 37 opened new positions — a net loss of 1 holder — while 87 trimmed existing stakes and 80 added.
The largest buyer was Maverick Capital, adding an estimated $16.8M. The largest seller was Wellington Management Group, cutting an estimated $30.3M.
- 246 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2020, down from 249 in Q3 2020.
- Funds reported $2.93B of Nektar Therapeutics stock for Q4 2020, up 1.8% quarter-over-quarter.
- 37 funds opened new Nektar Therapeutics positions in Q4 2020 and 38 closed out, a net change of -1 holder.
- The largest Nektar Therapeutics buyer in Q4 2020 was Maverick Capital, an estimated $16.8M added.
- The largest Nektar Therapeutics seller in Q4 2020 was Wellington Management Group, an estimated $30.3M sold.
Based on aggregated 13F filings for Q4 2020.